Why Tonix Pharmaceuticals (TNXP) Stock Is Plummeting Today

NEW YORK (TheStreet) -- Shares of Tonix Pharmaceuticals  (TNXP) plummeted 49.43% to $7.06 on Monday after the company announced its lead drug candidate for treating fibromyalgia came up short of the primary goal in a mid-stage trial.

Tonix's drug TNX-102 missed the mark in the study, which tested if the drug reduced patients' pain by the 12th week of the trial. TNX-102 did, however, improve sleep quality in patients, which was one of the important secondary goals of the trial, Tonix said.

Fibromyalgia is a chronic disease that causes widespread pain and lack of sleep in patients.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The company also announced it intended to discuss the results of the trial, as well as a design for a late-stage trial of TNX-102, with the FDA.

More than 2.1 million shared had changed hands as of 3:21 p.m., which eclipsed the average volume of 105,672.

TNXP Chart TNXP data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Stocks Finish Higher After Release of Fed Minutes

Stocks Finish Higher After Release of Fed Minutes